Modifying adipocyte and pre-adipocyte cell fate in fibroadipose tissue of secondary lymphedema
Modifying adipocyte and pre-adipocyte cell fate in fibroadipose tissue of secondary lymphedema
批准号:
10571049
负责人:
Shailesh Agarwal
金额:
$17.28万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-03-01 至 2028-02-28
关键词:
AchievementAddressAdipocytesAdipose tissueAffectAgonistApoptosisApoptoticAutologousAwardBioinformaticsBiologyCancer PatientCell Differentiation processCell SurvivalCell TherapyCellsChronicClinicalDataDepositionEducational workshopEngineeringEngraftmentEnvironmentEvaluationFaceFatty acid glycerol estersFunctional disorderFundingGoalsHindlimbHistologicImpairmentInstitutionK-Series Research Career ProgramsKnockout MiceLaboratoriesLeadershipLimb structureLocal TherapyLymphLymphaticLymphedemaMAP3K7 geneMapsMechanicsMediatorMentorsMentorshipMesenchymalMicroRNAsModificationMonitorMusObesityOligonucleotidesOperative Surgical ProceduresPathogenesisPathologicPathologyPatientsPhysiciansPlastic Surgical ProceduresPopulationPredispositionProcessProliferatingPublic HealthQuality of lifeResearchScientistSignal PathwaySignal TransductionSiteSwellingTamoxifenTechnical ExpertiseTherapeuticTimeTissuesTrainingTranslational ResearchUnited StatesWagesadipocyte biologyadipocyte differentiationadverse outcomeantagonistcareercell typechronic painexosomeexpectationexperiencegenetic signatureinhibitorinsightmouse modelopen woundpharmacologicpreventreceptorresearch and developmentrosiglitazonesecondary lymphedemasingle-cell RNA sequencingskillsstem cell biologystem cell fatestem cell populationstem cellssubcutaneoussuccesssymposiumtherapy adverse effecttranscriptome sequencingtranslational medicinetranslational therapeuticstreatment strategyuptake
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
Secondary lymphedema is a morbid condition affecting over 5 million patients in the United States.
Patients with this condition develop lymphatic retention, which progresses to irreversible subcutaneous
fibroadipose deposition in the affected extremity. As a result, patients experience chronic pain, decreased
mobility and function, open wounds, and overall reduced quality-of-life. In Aim 1, I will examine how a
stimulation of a signaling mediator which augments adipocyte differentiation may reduce overall fibroadipose
deposition by preventing the proliferation of pathologic stem cell populations. In Aim 2, I will examine how
inhibition of a pro-survival signaling mediator may impact adipocyte and pre-adipocyte survival. In the process,
I seek to understand whether specific subsets of these cells are more likely to undergo apoptosis. Finally, in
Aim 3, I seek to develop a local cell therapy which obviates the systemic adverse effects of therapies which
modify cell differentiation or survival. In the process, I will have developed a therapy which is capable of
secreting microRNA, paving the way for a new class of cell therapeutics.
The career development award is indispensable for my maturation as a physician-scientist, to serve as a
scientific and clinical leader performing research which is inspired by the challenges my patients face, rigorous
in its evaluation of the underlying pathogenesis of this condition, and translational in its consideration of
treatment strategies. I am supported by a team of mentors with expertise in stem cell and adipocyte biology,
clinical lymphedema management, and in academic plastic surgery leadership. I am also supported by a team
of additional scientific advisors with expertise in lymphedema biology, cell therapy, and translational medicine.
The institution is committed to my success, with protected time for activities proposed in this award, laboratory
space, salary support, and laboratory funding. During the 5-year career development award, I will build on my
previous expertise with monitoring stem cell fate using lineage-tracing mouse models, and add new scientific
expertise to my armamentarium with single-cell RNA sequencing and bioinformatics analysis. I will engage in
workshops and seminars to build on my technical skillset, and develop essential laboratory leadership skills.
Upon completion of my 4th year of the career development award, I will submit for my first R01 submission,
with the goal of further advancing findings obtained during my career development award. Upon completion of
the 5-year award period, I will expect to have established my scientific expertise in adipocyte biology, cell
therapy, and lymphedema, and established my technical expertise in lineage-tracing and RNA sequencing, to
contribute broadly to the scientific environment in my institution.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Regulation of compartmentalized cAMP signaling by mitochondria-associated spaces in adult ventricular myocytes
-
批准号:10522257
-
项目类别:
-
资助金额:$45.89万
-
财政年份:2022
-
负责人:Shailesh Agarwal
-
依托单位:
Regulation of compartmentalized cAMP signaling by mitochondria-associated spaces in adult ventricular myocytes
-
批准号:10645094
-
项目类别:
-
资助金额:$46.2万
-
财政年份:2022
-
负责人:Shailesh Agarwal
-
依托单位:
Use of skin grafts programmed to express VEGF-C with biosensor feedback regulation to treat lymphedema
-
批准号:10042514
-
项目类别:
-
资助金额:$19.9万
-
财政年份:2020
-
负责人:Shailesh Agarwal
-
依托单位:
Use of skin grafts programmed to express VEGF-C with biosensor feedback regulation to treat lymphedema
-
批准号:10249235
-
项目类别:
-
资助金额:$21.44万
-
财政年份:2020
-
负责人:Shailesh Agarwal
-
依托单位:
Role of mitochondria-associated spaces in the regulation of compartmentation of cAMP signaling
-
批准号:10332751
-
项目类别:
-
资助金额:$25.73万
-
财政年份:2019
-
负责人:Shailesh Agarwal
-
依托单位:
Role of mitochondria-associated spaces in the regulation of compartmentation of cAMP signaling
-
批准号:10077909
-
项目类别:
-
资助金额:$20.77万
-
财政年份:2019
-
负责人:Shailesh Agarwal
-
依托单位:
海外基金